Chemo Secrets From a Breast Cancer Survivor

Breast Cancer Survivors

Get Instant Access

1. Newton, H. B. (1994). Primary brain tumors: Review of etiology, diagnosis, and treatment. Am Fam Phys 49, 787-797.

2. Roberts, R., Lynch, C., Jones, M., Hart, M. (1991). Medulloblastoma: A population-based study of 532 cases. J Neuropathol Exp Neurol 50, 134-144.

3. Siffert, J., and Allen, J. C. (1997). Medulloblastoma. In Handbook of Clinical Neurology, Vol. 24 (68): Neuro-Oncology Part II. (C. J. Vecht Ed.), 8, 181-209. Elsevier Science, Amsterdam.

4. Tomlinson, F. H., Scheithauer, B. W., Meyer, F. B. et al. (1992). Medulloblastoma: I. Clinical, diagnostic, and therapeutic overview. J Child Neurol 7, 142-155.

5. Berger, M. S., Margrassi, L., and Geyer, R. (1995). Medulloblastoma and primitive neuroectodermal tumors. In Brain Tumors.

An Encyclopedic Approach. (A. H. Kaye, and E. R. Laws Eds.), 30, 561-574. Churchill Livingstone, Edinburgh.

6. Bloom, H. J. G., and Bessel, E. M. (1990). Medulloblastoma in adults: A review of 47 patients treated between 1952 and 1981. Int J Rad Oncol Biol Phys 18, 763-772.

7. Kunchner, L. J., Kuttesch, J., Hess, K., and Yung, W. K. A.

(2001). Survival and recurrence factors in adult medulloblastoma: The M. D. Anderson Cancer Center experience from 1978 to 1998. Neurooncol 3, 167-173.

8. Hung, K. L., Wu, C. M., Huang, J. S., and How, S. W. (1990). Familial medulloblastoma in siblings: Report in one family and review of the literature. Surg Neurol 33, 341-346.

9. Bondy, M., Wiencke, J., Wrensch, M., and Kyritsis, A. P. (1994). Genetics of primary brain tumors: a review. J Neurooncol 18, 69-81.

10. Cushing, H. (1930). Experiences with cerebellar medulloblastoma: a critical review. Acta Pathol Microbiol Scand 7, 1-86.

11. Mcintosh, N. (1979). Medulloblastoma: a changing prognosis. Arch Dis Child 54, 200-203.

12. Freeman, C. R., Taylor, R. E., Kortmann, R. D., and Carrie, C.

(2002). Radiotherapy for medulloblastoma in children: A perspective on current international clinical research efforts. Med Pediatr Oncol 39, 99-108.

13. Koeller, K. K., and Rushing, E. J. (2003). Medulloblastoma: A comprehensive review with radiologic-pathologic correlation. Radiographics 23, 1613-1637.

14. Rood, B. R., MacDonald, T. J., and Packer, R. J. (2004). Current treatment of medulloblastoma: Recent advances and future challenges. Semin Oncol 31, 666-675.

15. Newton, H. B. (2001). Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medullo-blastoma. Expert Opin Investig Drugs 10, 2089-2104.

16. Mazzola, C. A., and Pollack, I. F. (2003). Medulloblastoma. Curr Treat Options Neurol 5, 189-198.

17. Luh, G. Y., and Bird, C. R. (1999). Imaging of brain tumors in the pediatric population. Neuroimag Clin N Am 9, 691-716.

18. Fouladi, M., Gajjar, A., Boyett, J. M. et al (1999). Comparison of CSF cytology and spinal magnetic resonance imaging in the detection of leptomeningeal disease in pediatric medulloblas-toma or primitive neuroectodermal tumor. J Clin Oncol 17, 3234-3237.

19. Packer, R. J., and Finlay, J. L. (1988). Medulloblastoma: Presentation, diagnosis, and management. Oncol 2, 35-44.

20. Whelan, H. T., Krouwer, H. G., Schmidt, M. H., Reichert, K. W., and Kovnar, E. H. (1998). Current therapy and new perspectives in the treatment of medulloblastoma. Pediatr Neurol 18, 103-115.

21. Albright, A. L., Wisoff, J. M., Zeltzer, P. M. et al. (1996). Effects of medulloblastoma resections on outcome in children: A report from the Children's Cancer Group. Neurosurg 38, 265-271.

22. Sutton, L. N., Phillips, P. C., and Molloy, P. T. (1996). Surgical management of medulloblastoma. J Neurooncol 29, 9-21.

23. Paulino, A. C. (1997). Radiotherapeutic management of medulloblastoma. Oncol 11, 813-923.

24. Brand, W. N., Schneider, P. A., and Tokars, R. P. (1987). Long term results of a pilot study of low dose cranial-spinal irradiation for cerebellar medulloblastoma. Int J Radiat Oncol Biol Phys 13, 1641-1645.

25. Deutsch, M., Thomas, P. R. M., Krischer, J. et al. (1996). Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3600 cGy/20) with reduced neuraxis irradiation (2340 cGy/13) in patients with low-stage medulloblastoma. Pediatr Neurosurg 24, 167-177.

26. Thomas, P. R. M., Deutsch, M., Kepner, J. L. et al. (2000). Low-stage medulloblastoma: Final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin oncol 18, 3004-3011.

27. Packer, R. J., Goldwein, J., Nicholson, H. S. et al. (1999). Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group study. J Clin Oncol 17, 2127-2136.

28. Prados, M. D., Edwards, M. S. B., Chang, S. M. et al. (1999). Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: Results of a phase II study. Int J Radiat Oncol Biol Phys 43, 279-285.

29. Packer, R. J., Sutton, L. N., Atkins, T. E. et al. (1989). A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 70, 707-713.

30. Moore, B. D., Ater, J. L., and Copeland, D. R. (1992). Improved neuropsychological outcome in children with brain tumors diagnosed during infancy and treated without cranial irradiation. J Child Neurol 7, 281-290.

31. Silber, J. H., Radcliffe, J., Peckam, V. et al. (1992). Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score. J Clin Oncol 10, 1390-1396.

32. Cangir, A., Van Eys, J., Berry, D. H., Hvizdala, E., and Morgan, S. K. (1978). Combination chemotherapy with MOPP in children with recurrent brain tumors. Med Pediatr Oncol 4, 253-261.

33. Van Eys, J., Cangir, A., Coody, D., and Smith, B. (1985). MOPP regimen as primary chemotherapy for brain tumors in infants. J Neurooncol 3, 237-243.

34. Baram, T. Z., Van Eys, J., Dowell, R. E. et al. (1987). Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy. A preliminary report. Cancer 60, 173-177.

35. Ater, J. L., Van Eys, J., Woo, S. Y. et al. (1997). MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncol 32, 243-252.

36. Kretschmar, C. S., Tarbell, N. J., Kupsky, W. et al. (1989). Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report. J Neurosurg 71, 820-825.

37. Duffner, P. K., Horowitz, M. E., Krischer, J. P. et al. (1993). Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New Engl J Med 328:172501731.

38. Geyer, J. R., Zeltzer, P. M., Boyett, J. M. et al. (1994). Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Children's Cancer Group. J Clin Oncol 12, 1607-1615.

39. Razzouk, B. I., Heideman, R. L., Friedman, H. S. et al. (1995). A phase II evaluation of thiotepa followed by other multiagent chemotherapy regimens in infants and young children with malignant brain tumors. Cancer 75, 2762-2767.

40. Dupois-Girod, S., Hartmann, O., Benhamou, E. et al. (1996). Will high dose chemotherapy followed by autologous bone marrow transplantation supplant cranio-spinal irradiation in young children treated for medulloblastoma? J Neurooncol 27, 87-98.

41. Perez-Martinez, A, Quintero, V., Vicent, M. G., Sevilla, J., Diaz, M. A., and Madero, L. (2004). High-dose chemotherapy with autologous stem cell rescue as first line of treatment in young children with medulloblastoma and supratentorial neuroecto-dermal tumors. J Neurooncol 67, 101-106.

42. Tornesello, A., Mastrangelo, S., Bembo, D. et al. (1999). Progressive disease in children with medulloblastoma/ PNET during preradiation chemotherapy. J Neurooncol 45, 135-140.

43. Packer, R. J., Gajjar, A., Vezina, G. et al. (2004). 2340 cGy of craniospinal radiotherapy (CSRT) plus chemotherapy for children with "average-risk" medulloblastoma (MB): A prospective randomized Children's Oncology Group study (A9961). Neuro-Oncol 6:387.

44. Jakacki, R. I., Feldman, H., Jamison, C., Boaz, J. C., Luerssen, T. G., and Timmerman, R. (2004). A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Rad Oncol Biol Phys 60, 531-536.

45. Rutkowski, S., Bode, U., Deinlein, F. et al. (2004). Cure of children less than three years of age with medulloblastoma (M0/M1-stage) by postoperative chemotherapy only: Final results of the HIT-SKK'92 study. Neuro-Oncol 6, 469.

46. Packer, R. J. (1990). Chemotherapy for medulloblastoma/ primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 28, 823-828.

47. Gajjar, A., Kuhl, J., Epelman, S., Bailey, C., and Allen, J. (1999). Chemotherapy of medulloblastoma. Child's Nerv Syst 15, 554-562.

48. Evans, A. E., Jenkin, D. T., Sposto, R. et al. (1990). The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72, 572-582.

49. Tait, D. M., Thornton-Jones, H., Bloom, H. J. G., Lemerle, J., and Morris-Jones, P. (1990). Adjuvant chemotherapy for medullo-blastoma: the first multi-centre trial of the International Society of Pediatric Oncology (SIOP I). Eur J Cancer 26, 464-469.

50. Krischer, J. P., Ragab, A. H., Kun, L. et al. (1991). Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pedia-tric Oncology Group study. J Neurosurg 74, 905-909.

51. Bailey, C. A., Gnekow, S., Wellik, M. et al (1995). Prospective randomized trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Pediatric Oncology (SIOP) and the (German) Society of Pediatric Oncology (GPO): SIOP II. J Pediatr Hematol Oncol 25, 166-178.

52. Zeltzer, P. M., Boyett, J. M., Finlay, J. L. et al. (1999). Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: Conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17, 832-845.

53. Packer, R. J., Sutton, L. N., Goldwein, J. W. et al. (1991). Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J Neurosurg 74, 433-440.

54. Packer, R. J., Sutton, L. N., Elterman, R. et al. (1994). Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg 81, 690-698.

55. Ris, M. D., Packer, R., Goldwein, J., Jones-Wallace, D., and Boyett, R. M. (2001). Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medullo-blastoma: A Children's Cancer Group study. J Clin Oncol 19, 3470-3476.

56. Douglas, J. G., Barker, J. L., Ellenbogen, R. G., and Geyer, J. R. (2004). Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: Efficacy and patterns of failure. Int J Rad Oncol Biol Phys 58, 1161-1164.

57. Mosijczuk, A. D., Nigro, M. A., Thomas, P. R. M. et ah (1993). Preradiation chemotherapy in advanced medulloblastoma. A Pediatric Oncology Group pilot study. Cancer 72, 2755-2762.

58. Taylor, R. E., Bailey, C. C., Robinson, K. et al. (2003). Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study. J Clin Oncol 21, 1581-1591.

59. Stewart, C. F., Iacono, L. C., Chintagumpala, M. et al. (2004). Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supraten-torial primitive neuroectodermal tumor. J Clin Oncol 22, 3357-3365.

60. Allen, J. C., Donahue, B., Darossa, R., and Nirengerg, A. (1996). Hyperfractionated craniospinal radiotherapy and adjuvant chemotherapy for children with newly diagnosed medullo-blastoma and other primitive neuroectodermal tumors. Int J Rad Oncol Biol Phys 36, 1155-1161.

61. Crafts, D. C., Levin, V. A., Edwards, M. S., Pischer, T. L., and Wilson, C. B. (1978). Chemotherapy of recurrent medulloblas-toma with combined procarbazine, CCNU, and vincristine. J Neurosurg 49, 589-592.

62. Friedman, H. S., Mahaley, M. S., Schold, S. C. et al. (1986). Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma. Neurosurg 18, 335-340.

63. Lefkowitz, I. B., Packer, R. J., Siegel, K. R. et al. (1990). Results of treatment of children with recurrent medulloblastoma/primi-tive neuroectodermal tumors with lomustine, cisplatin, and vincristine. Cancer 65, 412-417.

64. Gentet, J. F., Doz, E., Bouffet, D. et al. (1994). Carboplatin and VP-16 in medulloblastoma: a phase II study of the French Society of Pediatric Oncology (SFOP). Med Pediatr Oncol 23, 422-427.

65. Carrie, C., Lasset, C., Alapetite, C. et al. (1994). Multivariate analysis of prognostic factors in adult patients with medullo-blastoma. Retrospective study of 156 patients. Cancer 74, 2352-2360.

66. Le, Q. T., Weil, M. D., Wara, W. M. et al. (1997). Adult medulloblastoma: An analysis of survival and prognostic factors. Cancer J Sci Am 3, 238-2.45.

67. Brandes, A. A., Palmisano, V., and Monfardini, S. (1999). Medulloblastoma in adults: clinical characteristics and treatment. Cancer Treat Rev 25, 3-12.

68. Chan, A. W., Tarbell, N. J., Black, P. M. et al. (2000). Adult medulloblastoma: Prognostic factors and patterns of relapse. Neurosurg 47, 623-632.

69. Malheiros, S. M. F., Franco, C. M. R., Stavale, J. N. et al. (2002). Medulloblastoma in adults: a series from Brazil. J Neurooncol 60, 247-253.

70. Kortmann, R. D., and Brandes, A. A. (2003). Current and future strategies in the management of medulloblastoma in adults. FORUM Trends Exp Clin Med 13, 99-110.

71. Eisenstat, D. D. (2004). Clinical management of medulloblas-toma in adults. Expert Rev Anticancer Ther 4, 795-802.

72. Brandes, A. A., Ermani, M., Amista, P. et al. (2003). The treatment of adults with medulloblastoma: A prospective study. Int J Rad Oncol Biol Phys 57, 755-761.

73. Greenberg, H. S., Chamberlain, M. C., Glantz, M. J., and Wang, S (2001). Adult medulloblastoma: Multiagent chemotherapy. Neuro-Oncol 3, 29-34.

74. Mahoney, D. H., Strother, D., Camitta, B. et al. (1996). High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: A pilot Pediatric Oncology Group study. J Clin Oncol 14, 382-388.

75. Finlay, J. L., Goldman, S., Wong, M. C. et al. (1996). Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. J Clin Oncol 14, 2495-2503.

76. Graham, M. L., Herndon, J. E., Casey, J. R. et al. (1997). Highdose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. J Clin Oncol 15, 1814-1823.

77. Dunkel, I. J., Boyett, J. M., Yates, A. et al. (1998). High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 16, 222-228.

78. Gururangan, S., Dunkel, I. J., Goldman, S. et al. (1998). Myeloablative chemotherapy with autologous bone marrow rescue in young children with recurrent malignant brain tumors. J Clin Oncol 16, 2486-2493.

79. Millot, F., Delval, O., Giraud, C. et al. (1999). High-dose chemotherapy with hematopoietic stem cell transplantation in adults with bone marrow relapse of medulloblastoma: report of two cases. Bone Marrow Transplan 24, 1347-1349.

80. Strother, D., Ashley, D., Kellie, S. J. et al. (2001). Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniosp-inal radiotherapy: Results of a collaborative study. J Clin Oncol (2001) 19, 2696-2704.

81. Zia, M. I., Forsyth, P., Chaudhry, A., Russell, J., and Stewart, D. A. (2002). Possible benefits of high-dose chemotherapy and autologous stem cell transplantation for adults with recurrent medulloblastoma. Bone Marrow Transplan 30, 565-569.

82. Mclenden, R. E., Enterline, D. S., Tien, R. D., Thorstad, W. L., and Bruner, J. M. (1998). Tumors of central neuroepithelial origin. In Russell & Rubinstein's Pathology of Tumors of the Nervous System (D. D. Bigner, R. E. McLendon, and J. M. Bruner, Eds.) 6th ed., pp. 456-479, Arnold Press, London.

83. Friedman, H. S., Oakes, W. J., Bigner, S. H., Wikstrand, C. J., and Bigner, D. D. (1991). Medulloblastoma: tumor biological and clinical perspectives. J Neurooncol 11, 1-15.

84. Tomlinson, F. H., Scheithauer, B. W., and Jenkins, R. B. (1992). Medulloblastoma: II. A pathobiologic overview. J Child Neurol 7, 240-252.

85. Gilbertson, R. J. (2004). Medulloblastoma: signaling a change in treatment. Lancet Oncol 5, 209-218.

86. Shapiro, J. R., and Coons, S. W. (1998). Genetics of adult malignant gliomas. BNI Quarterly 14, 27-42.

87. Saylors, R. L., Sidransky, D., Friedman, H. S. et al. (1991). Infrequent p53 mutations in medulloblastomas. Cancer Res 51, 4721-4723.

88. Biegel, J. A., Burk, C. D., Barr, F. G., and Emanuel, B. S. (1992). Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors of the central nervous system. Cancer Res 52, 3391-3395.

89. Garson, J. A., Pemberton, L. F., Sheppard, P. W. et al. (1989). N-myc gene expression and oncoprotein characterisation in medulloblastoma. Br J Cancer 59, 889-894.

90. Macgregor, D. N., and Ziff, E. B. (1990). Elevated c-myc expression in childhood medulloblastomas. Pediatr Res 28, 63-68.

91. Bigner, S. H., Friedman, H. S., Vogelstein, B., Oakes, W. J., and Bigner, D. D. (1990). Amplification of the c-myc gene in human medulloblastoma cell lines and xenografts. Cancer Res 50, 2347-2350.

92. Tomlinson, F. H., Jenkins, R. B., Scheithauer, B. W. et ah (1994). Aggressive medulloblastoma with high-level N-myc amplification. Mayo Clin Proc 69, 359-365.

93. Bruggers, C. S., Tai, K. F., Murdock, T. et al. (1998). Expression of the C-myc protein in childhood medulloblastoma. J Pediatr Hematol Oncol 20, 18-25.

94. Herms, J., Neidt, I., Luscher, B. et al. (2000). C-myc expression in medulloblastoma and its prognostic value. Int J Cancer 89, 395-402.

95. Stearns, D., Chaudhry, A., Burger, P. C., and Eberhart, C. G. (2004). C-myc expression recapitulates the large cell/anaplas-tic medulloblastoma phenotype in xenografts. Neuro-Oncol 6, 414.

96. Wang, J. Y., Valle, L. D., Gordon, J. et al. (2001). Activation of the IGF-IR system contributes to malignant growth of human and mouse medulloblastomas. Oncogene 20, 3857-3868.

97. Gilbertson, R. J., Perry, R. H., Kelly, P. J., Pearson, A. D. J., and Lunec, J. (1997). Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 57, 3272-3280.

98. Gilbertson, R. J., Clifford, S. C., Macmeekin, W. et al. (1998). Expression of the ErbB-Neuregulin signaling network during human cerebellar development: Implications for the biology of medulloblastoma. Cancer Res 58, 3932-3941.

99. Polakis, P. (2000). Wnt signaling and cancer. Genes Dev 14, 1837-1851.

100. Henderson, B. R., and Fagotto, F. (2002). The ins and outs of APC and beta-catenin nuclear transport. EMBO Rep 3, 834-839.

101. Zurawel, R. H., Chiappa, S. A., Allen, C., and Raffel, C. (1998). Sporadic medulloblastomas contain oncogenic ß-catenin mutations. Cancer Res 58, 896-899.

102. Koch, A., Waha, A., Tonn, J. C. et al. (2001). Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93, 445-449.

103. Fruhwald, M. C., O'dorisio, M. S., Pietsch, T., and Reubi, J. C. (1999). High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: Implications for diagnosis and therapy. Pediatr Res 45, 697-708.

104. Fruhwald, M. C., O'dorisio, M. S., Fleitz, J., Pietsch, T., and Reubi, J. C. (1999). Vasoactive intestinal peptide (VIP) and VIP receptors: Gene expression and growth modulation in medulloblastoma and other central primitive neuroectoder-mal tumors of childhood. Int J Cancer 81, 165-173.

105. Grotzer, M. A., Janss, A. J., Fung, K. M. et al. (2000). TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18, 1027-1035.

106. Ming, J. E., Roesseler, E., and Muenke, M. (1998). Human developmental disorders and the sonic hedgehog pathway. Mol Med Today Aug: 343-349.

107. Ingham, P. W. (1998). The patched gene in development and cancer. Curr Opin Gen Devel 8, 88-94.

108. Wicking, C., Smyth, I., and Bale, A. (1999). The hedgehog signaling pathway in tumorigenesis and development. Oncogene 18, 7844-7851.

109. Saldanha, G. (2001). The hedgehog signaling pathway and cancer. J Pathol 193, 427-432.

110. Vortmeyer, A. O., Stavrou, T., Selby, D. et al. (1999). Deletion analysis of the adenomatous polyposis coli and PTCH gene loci in patients with sporadic and nevoid basal cell carcinoma syndrome-associated medulloblastoma. Cancer 85, 2662-2667.

111. Wetmore, C., Eberhart, D. E., and Curran, T. (2000). The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res 60, 2239-2246.

112. Zurawel, R. H., Allen, C., Wechsler-Reya, R., Scott, M. P., and Raffel, C. (2000). Evidence that haploinsufficiency of PTCH leads to medulloblastoma in mice. Genes Chromosomes Cancer 28, 77-81.

113. Corcoran, R. B., and Scott, M. P. (2001). A mouse model for medulloblastoma and basal cell nevus syndrome. J Neuro-oncol 53, 307-318.

114. Hasselager, G., and Holland, E. C. (2003). Using mice to decipher the molecular genetics of brain tumors. Neurosurg 53, 685-695.

115. Wetmore, C., Eberhart, D. E., and Curran, T. (2001). Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res 61, 513-516.

116. Wechsler-Reya, R. J., Oliver, T. G., Grasfeder, L. L. et al. (2003). Sonic hedgehog-induced proliferation of neuronal precursors is mediated by N-myc and cyclin D1. Proc Am Assoc Cancer Res 44, 1193.

117. Hallahan, A. R., Pritchard, J. I., Hansen, S. et al. (2004). The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medullo-blastomas. Cancer Res 64, 7794-7800.

118. Wolter, M., Reifenberger, J., Sommer, C., Ruzicka, T., and Reifenberger, G. (1997). Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 57, 2581-2585.

119. Pietsch, T., Waha, A., Koch, A. et al. (1997). Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of drosophila patched. Cancer Res 57, 2085-2088.

120. Raffel, C., Jenkins, R. B., Frederick, L. et al. (1997). Sporadic medulloblastomas contain PTCH mutations. Cancer Res 57, 842-845.

121. Zurawel, R. H., Allen, C., Chiappa, S. et al. (2000). Analysis of PTCH/SMO/SHH pathway genes in medulloblastoma. Genes Chromosomes Cancer 27, 44-51.

122. Dong, J., Gailani, M. R., Pomeroy, S. L., Reardon, D., and Bale, A. E. (2000). Identification of patched mutations in medullo-blastomas by direct sequencing. Human Mut (Online) 339, 1-7.

123. Smyth, I., Narang, M. A., Evans, T. et al. (1999). Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene in basal cell carcinoma and medullo-blastoma on chromosome 1p32. Human Mol Genet 8, 291-297.

124. Reifenberger, J., Wolter, M., Weber, R. G. et al. (1998). Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 58, 1798-1803.

125. Erez, A., Ilan, T., Amariglio, N. et al. (2002). Gli3 is not mutated commonly in sporadic medulloblastomas. Cancer 95, 28-31.

126. Taylor, M. D., Liu, L., Raffel, C. et al. (2002). Mutations in SUFU predispose to medulloblastoma. Nature Genet 31, 306-310.

127. Kinzler, K. W., Bigner, S. H., Bigner, D. D. et al. (1987). Identification of an amplified, highly expressed gene in a human glioma. Science 236, 70-73.

128. Katayama, M., Yoshida, K., Ishimori, H. et al. (2002). Patched and smoothened mRNA expression in human astrocytic tumors inversely correlates with histological malignancy. J Neurooncol 59, 107-115.

129. Brandes, A. A., Paris, M. K., and Basso, U. (2003). Medullo-blastomas: do molecular and biologic markers indicate different prognoses and treatments? Expert Rev Anticancer Ther 3, 615-620.

130. Incardona, J. P., Gaffield, W., Kapur, R. P., and Roelink, H. (1998). The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Develop 125, 3553-3562.

131. Taipale J, Chen, J. K., Cooper, M. K. et al. (2000). Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 406, 1005-1009.

132. Chen, J. K., Taipale J, Cooper, M. K. et al. (2002). Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Devel 16, 2743-2748.

133. Berman, D. M., Karhadkar, S. S., Hallahan, A. R. et al. (2002). Medulloblastoma growth inhibition by hedgehog pathway blockage. Science 297, 1559-1561.

134. Chen, J. K., Taipale, J., Young, K. E., Maiti, T., and Beachy, P. A. (2002). Small molecule modulation of smoothened activity. Proc Natl Acad Sci 99, 14071-14076.

135. Romer, J. T., Kimura, H., Magdaleno, S. et al. (2004). Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1 + /- p53-/- mice. Cancer Cell 6, 229-240.

136. Duffner, P. D., Cohen, M. E., and Thomas, P. (1983). Late effects of treatment on the intelligence of children with posterior fossa tumors. Cancer 51, 233-237.

137. Duffner, P. K., Cohen, M. E., and Parker, M. S. (1988). Prospective intellectual testing in children with brain tumors. Ann Neurol 23, 575-579.

138. Duffner, P. K., and Cohen, M. E. (1991). The long-term effects of central nervous system therapy on children with brain tumors. Neurol Clin 9, 479-495.

139. Mulhern, R. K., Ochs, J., and Kun, L. E. (1991). Changes in intellect associated with cranial radiaton therapy. In Radiation Injury to the Nervous System (P. H. Gutin, S. A. Leibel, and G. E. Sheline, Eds.), pp. 325-340, Ravenpress, New York.

140. Mulhern, R. K., Hancock, J., Fairclough, D., and Kun, L. (1992). Neuropsychological status of children treated for brain tumors: A critical review and integrative analysis. Med Pediatr Oncol 20, 181-191.

141. Silverman, C. L., Palkes, H., Talent, B. et al. (1984). Late effects of radiotherapy on patients with cerebellar medulloblastoma. Cancer 54, 825-829.

142. Johnson, D. L., Mccabe, M. A., Nicholson, S. H. et al. (1994). Quality of long-term survival in young children with medulloblastoma. J Neurosurg 80, 1004-1010.

143. Dennis, M., Spiegler, B. J., Hetherington, C. R., and Greenberg, M. L. (1996). Neuropsychological sequelae of the treatment of children with medulloblastoma. J Neurooncol 29, 91-101.

144. Mulhern, R. K., Kepner, J. L., Thomas, P. R. et al. (1998). Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: A Pediatric Oncology Group study. J Clin Oncol 16, 1723-1728.

145. Walter, A. W., Mulhern, R. K., Gajjar, A. et al. (1999). Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children's Research Hospital. J Clin Oncol 17, 3720-3728.

146. Palmer, S. L., Goloubeva, O., Reddick, W. E. et al. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: A longitudinal analysis. J Clin Oncol 19, 2302-2308.

147. Mulhern, R. K., Reddick, Palmer, S. L. et al. (1999). Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol 46, 834-841.

148. Mulhern, R. K., Palmer, S. L., Reddick, W. E. et al. (2001). Risks of young age for selected neurocognitive deficits in medullo-blastoma are associated with white matter loss. J Clin Oncol 19, 472-479.

149. Newton, H. B., Turowski, R. C., Stroup, T. J., and McCoy, L. K. (1999). Clinical presentation, diagnosis, and pharmacotherapy of patients with primary brain tumors. Ann Pharmacother 33, 816-832.

150. Newton, H. B. (2000). Novel chemotherapeutic agents for the treatment of brain cancer. Expert Opin Invest Drugs 9, 2815-2829.

151. Garrett, M. D., and Workman, P. (1999). Discovering novel chemotherapeutic drugs for the third millenium. Eur J Cancer 35, 2010-2030.

152. Newton, H. B. (2004). Molecular neuro-oncology and the development of "targeted" therapeutic strategies for brain tumors. Part 2 - PI3K/Akt/PTEN, mTOR, SHH/PTCH, and angiogenesis. Expert Rev Anticancer Ther 4, 105-128.

153. Henrikkson, M., and Luscher, B. (1996). Proteins of the myc network: essential regulator of cell growth and differentiation. Adv Cancer Res 68, 109-182.

154. Fernandez-Teijeiro, A., Betensky, R. A., Sturla, L. M., Kim, J. Y. H., Tamayo, P., and Pomeroy, S. L. (2004). Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 22, 994-998.

155. Gajjar, A., Hernan, R., Kocak, M. et al. (2004). Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medullo-blastoma. J Clin Oncol 22, 984-993.

156. Lamont, J. M., McManamy, C. S., Pearson, A. D., Clifford, S. C., and Ellison, D. W. (2004). Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10, 5482-5493.

157. Greenberg, S. A. (2001). DNA microarray gene expression analysis technology and its application to neurological disorders. Neurol 57, 755-761.

158. Gilbertson, R., Wickramasinghe, C., Hernan, R. et al. (2001). Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer 85, 705-712.

Ubiquitination & Degradation

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment